U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30O2
Molecular Weight 314.4617
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CANNABIDIOL

SMILES

CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1

InChI

InChIKey=QHMBSVQNZZTUGM-ZWKOTPCHSA-N
InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H30O2
Molecular Weight 314.4617
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24854329 | https://www.gwpharm.com/products-pipeline

Cannabidiol is the major nonpsychoactive ingredient in cannabis. Cannabidiol demonstrates a range of effects that may be therapeutically useful, including anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psychotic, and anti-anxiety properties. Exact mechanism of action of cannabidiol is not known, but may include effects on the orphan G-protein-coupled receptor GPR55; the transient receptor potential of vanilloid type-1 channel; the 5-HT1a receptor; and the α3 glycine receptors. GW Pharmaceuticals successfully developed the world’s first prescription medicine derived from the cannabis plant, Sativex® (buccal spray containing delta-9-tetrahydrocannabinol and cannabidiol) now approved in over 29 countries outside of the United States for the treatment of spasticity due to Multiple Sclerosis. GW Pharmaceuticals is developing Epidiolex® (a liquid formulation of pure plant-derived cannabidiol) for certain rare and severe early-onset, drug-resistant epilepsy syndromes.

Originator

Sources: Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc. 1940;62:196-200. | Mechoulam R, Shvo Y. Hashish. 1. Structure of Cannabidiol. Tetrahedron. 1963;19(12):2073-8
Curator's Comment: Although cannabidiol was isolated from marijuana extract in 1940 by Adams et al., for almost 25 years no further work has been reported, except for a few early works about its isolation. Only in 1963 its exact chemical structure was elucidated by Mechoulam and Shvo. https://www.ncbi.nlm.nih.gov/pubmed/18833429

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SATIVEX

Approved Use

Sativex is used in multiple sclerosis (MS) to improve symptoms related to muscle stiffness. This is also called “spasticity”. Spasticity means there is an increase in ‘muscle tone’ which makes the muscles feel more stiff or rigid. This means it is more difficult than normal to move the muscle. Sativex is used when other medicines have not helped your muscle stiffness.
Primary
SATIVEX

Approved Use

SATIVEX® buccal spray is indicated as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain.
Primary
EPIDIOLEX

Approved Use

Unknown
Primary
EPIDIOLEX

Approved Use

Unknown
Primary
EPIDIOLEX

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
330.3 ng/mL
750 mg 2 times / day multiple, oral
dose: 750 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
541.2 ng/mL
1500 mg 2 times / day multiple, oral
dose: 1500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
292.4 ng/mL
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
327 ng/mL
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
782 ng/mL
6000 mg single, oral
dose: 6000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1588 ng/mL
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1745 ng × h/mL
750 mg 2 times / day multiple, oral
dose: 750 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3236 ng × h/mL
1500 mg 2 times / day multiple, oral
dose: 1500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1618 ng × h/mL
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2198 ng × h/mL
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3900 ng × h/mL
6000 mg single, oral
dose: 6000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8670 ng × h/mL
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
56.41 h
750 mg 2 times / day multiple, oral
dose: 750 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
60.54 h
1500 mg 2 times / day multiple, oral
dose: 1500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
14.43 h
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
15.42 h
6000 mg single, oral
dose: 6000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
6%
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6%
6000 mg single, oral
dose: 6000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANNABIDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Disc. AE: Transaminases increased...
Other AEs: Transaminases increased, Decreased appetite...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1.3%)
Other AEs:
Transaminases increased (8%)
Decreased appetite (16%)
Diarrhea (9%)
Weight decreased (3%)
Abdominal discomfort (3%)
Somnolence (23%)
Sedation (3%)
Lethargy (4%)
Fatigue (11%)
Malaise (11%)
Asthenia (11%)
Irritability (9%)
Agitation (9%)
Insomnia (11%)
Sleep disorder (11%)
Poor quality sleep (11%)
Aggression (3%)
Anger (3%)
Drooling (1%)
Salivary hypersecretion (1%)
Gait disturbance (3%)
Infection viral (7%)
Pneumonia (8%)
Fungal infection (1%)
Infection NOS (25%)
Rash (7%)
Hypoxia (3%)
Respiratory failure (3%)
Sources:
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Disc. AE: Transaminases increased...
Other AEs: Transaminases increased, Decreased appetite...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (5.9%)
Other AEs:
Transaminases increased (16%)
Decreased appetite (22%)
Diarrhea (20%)
Weight decreased (5%)
Abdominal discomfort (3%)
Somnolence (25%)
Sedation (6%)
Lethargy (8%)
Fatigue (12%)
Malaise (12%)
Asthenia (12%)
Irritability (5%)
Agitation (5%)
Aggression (5%)
Anger (5%)
Drooling (4%)
Salivary hypersecretion (4%)
Gait disturbance (2%)
Infection viral (11%)
Pneumonia (5%)
Fungal infection (3%)
Infection NOS (21%)
Rash (13%)
Hypoxia (3%)
Gastroenteritis (4%)
Insomnia (5%)
Sleep disorder (5%)
Poor quality sleep (5%)
Respiratory failure (3%)
Sources:
50 mg/kg/day 1 times / day multiple, oral
Dose: 50 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg/kg/day, 1 times / day
Sources:
healthy, adult
n = 5
Health Status: healthy
Age Group: adult
Population Size: 5
Sources:
AEs

AEs

AESignificanceDosePopulation
Drooling 1%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Fungal infection 1%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Salivary hypersecretion 1%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Transaminases increased 1.3%
Disc. AE
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Asthenia 11%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Fatigue 11%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Insomnia 11%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Malaise 11%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Poor quality sleep 11%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Sleep disorder 11%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Decreased appetite 16%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Somnolence 23%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Infection NOS 25%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Abdominal discomfort 3%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Aggression 3%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Anger 3%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Gait disturbance 3%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Hypoxia 3%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Respiratory failure 3%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Sedation 3%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Weight decreased 3%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Lethargy 4%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Infection viral 7%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Rash 7%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Pneumonia 8%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Transaminases increased 8%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Agitation 9%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Diarrhea 9%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Irritability 9%
10 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 75
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 75
Sources:
Infection viral 11%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Asthenia 12%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Fatigue 12%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Malaise 12%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Rash 13%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Transaminases increased 16%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Gait disturbance 2%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Diarrhea 20%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Infection NOS 21%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Decreased appetite 22%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Somnolence 25%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Abdominal discomfort 3%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Fungal infection 3%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Hypoxia 3%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Respiratory failure 3%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Drooling 4%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Gastroenteritis 4%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Salivary hypersecretion 4%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Aggression 5%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Agitation 5%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Anger 5%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Insomnia 5%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Irritability 5%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Pneumonia 5%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Poor quality sleep 5%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Sleep disorder 5%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Weight decreased 5%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Transaminases increased 5.9%
Disc. AE
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Sedation 6%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
Lethargy 8%
20 mg/kg/day 1 times / day multiple, oral
Recommended
Dose: 20 mg/kg/day, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg/kg/day, 1 times / day
Sources:
unhealthy, 14 years (range: 2 - 48 years)
n = 238
Health Status: unhealthy
Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
Age Group: 14 years (range: 2 - 48 years)
Sex: M+F
Population Size: 238
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
yes
yes
yes
yes
likely
Comment: Co-administration with moderate or strong inhibitors of CYP3A4 or CYP2C19 is predicted to increase CBD plasma concentrations which may increase the risk CBD toxicities.
Page: 7.0
yes
likely
Comment: Co-administration with moderate or strong inhibitors of CYP3A4 or CYP2C19 is predicted to increase CBD plasma concentrations which may increase the risk CBD toxicities.
Page: 7.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
2001 Oct
Medicinal use of cannabis: history and current status.
2001 Summer
The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection.
2001 Summer
Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats.
2002 Apr 16
Hair analysis for delta(9)-THC, delta(9)-THC-COOH, CBN and CBD, by GC/MS-EI. Comparison with GC/MS-NCI for delta(9)-THC-COOH.
2002 Aug 14
Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects.
2002 Dec 31
CB(1) receptor antagonist SR141716A inhibits Ca(2+)-induced relaxation in CB(1) receptor-deficient mice.
2002 Feb
The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.
2002 Jan
Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists.
2002 May
Cannabidiol: an overview of some pharmacological aspects.
2002 Nov
Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia.
2002 Nov 15
Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery.
2003 Apr
The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
2003 Aug
Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors.
2003 Aug 8
Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects?
2003 Dec
Nonpsychotropic cannabinoid receptors regulate microglial cell migration.
2003 Feb 15
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
2003 Feb 25
[Weather-induced changes in cannabinoid content of hair].
2003 Jan-Feb
Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils.
2003 Jul 31
Gateways to clinical trials.
2003 Jun
Simultaneous detection of some drugs of abuse in saliva samples by SPME technique.
2003 Jun 24
Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor.
2003 Mar
G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current.
2003 Nov 14
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
2003 Nov 8
Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
2003 Nov 8
Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells.
2003 Oct
Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes.
2003 Sep
Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells.
2004 Apr
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.
2004 Aug
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.
2004 Dec
Effects of cannabidiol (CBD) on regional cerebral blood flow.
2004 Feb
Determination of cannabinoids in hemp food products by use of headspace solid-phase microextraction and gas chromatography-mass spectrometry.
2004 Jan
Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew).
2004 Jan
Synthesis and antitumor activity of quinonoid derivatives of cannabinoids.
2004 Jul 15
Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol.
2004 Mar
A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis.
2004 Mar
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.
2004 Mar
6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist.
2004 Mar 8
Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.
2004 May
NMR assignments of the major cannabinoids and cannabiflavonoids isolated from flowers of Cannabis sativa.
2004 Nov-Dec
Cannabinoids in hair: strategy to prove marijuana/hashish consumption.
2004 Oct 29
Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.
2004 Sep
Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.
2004 Sep
The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro.
2005 Feb
Marijuana extracts possess the effects like the endocrine disrupting chemicals.
2005 Jan 31
Flavonoid glycosides and cannabinoids from the pollen of Cannabis sativa L.
2005 Jan-Feb
CB1 cannabinoid receptor-mediated modulation of food intake in mice.
2005 Jun
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
2005 Jun-Jul
Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids.
2005 Sep
Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits.
2005 Sep
Patents

Patents

Sample Use Guides

SATIVEX® is provided as a buccal spray in a 5.5 ml vial, with each 100 microlitre spray providing 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). In patients with multiple sclerosis, the median daily dosage of SATIVEX® in the extension phase of the 4-week clinical trial was 5 sprays per day. The majority of patients required 12 sprays or less; dosage should be adjusted as needed and tolerated. There is limited experience with doses higher than 12 sprays per day. Some patients may require and may tolerate a higher number of sprays. In patients with pain in cancer, the median daily dosage of SATIVEX® was 8 actuations (sprays).
Route of Administration: Topical
in vitro pre-treatment of Human Gingival Mesenchymal Stem Cells with 5 uM Cannabidiol (CBD) can influence their expression profile
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:30:49 GMT 2023
Edited
by admin
on Sat Dec 16 16:30:49 GMT 2023
Record UNII
19GBJ60SN5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CANNABIDIOL
INCI   INN   MART.   MI   USAN   WHO-DD  
USAN   INN   INCI  
Official Name English
CANNABIDIOL [USAN]
Common Name English
CANNABIDIOL [USP-RS]
Common Name English
.DELTA.1(2)-TRANS-CANNABIDIOL
Common Name English
Cannabidiol [WHO-DD]
Common Name English
(-)-CANNABIDIOL
Common Name English
EPIDIOLEX
Brand Name English
CANNABIDIOL [MART.]
Common Name English
CARDIOLRX
Brand Name English
2-((1R,6R)-3-METHYL-6-(PROP-1-EN-2-YL)CYCLOHEX-2-EN-1-YL)-5-PENTYLBENZENE-1,3-DIOL
Systematic Name English
2-((1R,6R)-3-METHYL-6-(1-METHYLETHENYL)CYCLOHEX-2-ENYL)-5-PENTYLBENZENE-1,3-DIOL
Systematic Name English
CANNABIDIOL [INCI]
Common Name English
BTX-1503
Code English
(-)-CBD
Common Name English
GWP-42003
Code English
CANNABIDIOL [MI]
Common Name English
CBD
Common Name English
BTX-1204
Code English
CANNABIDIOL [ORANGE BOOK]
Common Name English
1,3-BENZENEDIOL, 2-((1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL)-5-PENTYL-
Systematic Name English
CANNABIDIOL SOLUTION [USP-RS]
Common Name English
GWP-42003-P
Code English
cannabidiol [INN]
Common Name English
GWP42003
Code English
(-)-TRANS-CANNABIDIOL
Common Name English
GWP42003-P
Code English
Classification Tree Code System Code
EU-Orphan Drug EU/3/17/1959
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 471815
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 510716
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
NCI_THESAURUS C274
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 914322
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
NCI_THESAURUS C1742
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 444814
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 409313
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 860921
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 609617
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
DSLD 3397 (Number of products:162)
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 617417
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 521416
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
WHO-ATC N03AX24
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 452614
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 620417
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 696519
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 734820
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 806620
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 545316
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 482315
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 656618
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 736020
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 439414
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 819221
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 538916
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
WHO-ATC N02BG10
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 763820
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 486115
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 610117
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 488315
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 421213
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 628818
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 549616
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 498215
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 438214
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 668918
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 734620
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 860821
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
FDA ORPHAN DRUG 450814
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
NCI_THESAURUS C105578
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
Code System Code Type Description
RXCUI
2045371
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
RS_ITEM_NUM
1089149
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
ChEMBL
CHEMBL190461
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
LACTMED
Cannabidiol
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
USAN
CD-48
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
EVMPD
SUB26600
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
NCI_THESAURUS
C118452
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
WIKIPEDIA
CANNABIDIOL
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
CHEBI
69478
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
RS_ITEM_NUM
1089161
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
ALTERNATIVE
INN
10423
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
DRUG BANK
DB09061
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
DAILYMED
19GBJ60SN5
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
DRUG CENTRAL
5288
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
FDA UNII
19GBJ60SN5
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
CAS
13956-29-1
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
PUBCHEM
644019
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID00871959
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
SMS_ID
100000091179
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
MESH
D002185
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY
MERCK INDEX
m3020
Created by admin on Sat Dec 16 16:30:52 GMT 2023 , Edited by admin on Sat Dec 16 16:30:52 GMT 2023
PRIMARY Merck Index
Related Record Type Details
TARGET->INVERSE AGONIST
METABOLIC ENZYME -> SUBSTRATE
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT
Cannabidiol Class | Anxiolytic Antipsychotic | Analgesic | Anti-inflammatory | Antioxydant | Antispasmodic
TARGET -> INHIBITOR
TARGET -> ACTIVATOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
Responsible for a drug interaction with clobazam. Mean increase in clozabam and N-desmethylclozabam levels was 60% and 500%, respectively, after 4 weeks of concomitant therapy.
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TARGET->INVERSE AGONIST
Related Record Type Details
METABOLITE -> PARENT
MINOR
METABOLITE INACTIVE -> PARENT
The major circulating metabolites include 7-carboxy-cannabidiol (7-COOH-CBD), which was approximately 40-fold higher than the parent.
MAJOR
METABOLITE -> PARENT
MAJOR
METABOLITE -> PARENT
MINOR
METABOLITE -> PARENT
MINOR
METABOLITE -> PARENT
METABOLITE -> PARENT
MINOR
METABOLITE ACTIVE -> PARENT
The major circulating metabolites include 7-hydroxy-cannabidiol (7-OH-CBD), which was approximately 38% of the parent based on AUC of cannabidiol.
MAJOR
METABOLITE -> PARENT
MINOR
METABOLITE -> PARENT
MAJOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC TWICE-DAILY DOSING FOR 7 DAYS